{"id":20148,"date":"2024-07-29T07:48:13","date_gmt":"2024-07-29T05:48:13","guid":{"rendered":"https:\/\/www.m-q.ch\/?p=20148"},"modified":"2024-07-25T13:52:47","modified_gmt":"2024-07-25T11:52:47","slug":"amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick","status":"publish","type":"post","link":"https:\/\/www.m-q.ch\/it\/amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick\/","title":{"rendered":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick"},"content":{"rendered":"
\"\"
I co-fondatori di Amporin: il CSO Dr Herv\u00e9 Schaffhauser, il CEO Dr Kelvin Stott e il CMO Prof Daniel Umbricht. (Immagine: www.venturekick.ch)<\/figcaption><\/figure>\n

Oltre 50 malattie degenerative mortali, tra cui il morbo di Alzheimer, il Parkinson, il diabete di tipo II e molte malattie neurodegenerative rare, sono legate al misfolding e all'aggregazione delle proteine. Queste malattie colpiscono pi\u00f9 di mezzo miliardo di persone in tutto il mondo e causano 3,6 milioni di vittime ogni anno, con un costo per la societ\u00e0 di circa 3 miliardi di dollari all'anno. Ad oggi, non esistono trattamenti efficaci in grado di arrestare o invertire la progressiva degenerazione.\u00a0<\/p>\n

Amporin Pharmaceuticals mira a sviluppare una nuova classe di farmaci a piccole molecole che bloccano ed eliminano gli oligomeri solubili e i pori tossici nelle membrane cellulari. Queste sostanze tossiche si accumulano e distruggono le cellule creando buchi nelle membrane cellulari, portando alla perdita dell'omeostasi e alla progressiva degenerazione. L'azienda intende sviluppare e commercializzare i primi trattamenti orali modificanti la malattia efficaci e acuti per un massimo di sei malattie principali, tra cui il morbo di Alzheimer e il diabete di tipo II, con un'attenzione iniziale al morbo di Parkinson e alla SLA (sclerosi laterale amiotrofica).<\/p>\n

La sola malattia di Parkinson colpisce circa un milione di persone negli Stati Uniti e circa dieci milioni di persone nel mondo. L'attuale mercato globale dei farmaci per la malattia di Parkinson \u00e8 di circa 6 miliardi di dollari all'anno, con un mercato potenziale di 15 miliardi di dollari all'anno per i primi trattamenti efficaci che modificano la malattia.<\/p>\n

I 150.000 franchi di Venture Kick permetteranno all'azienda di stabilire le sue attivit\u00e0 principali e di creare un pacchetto completo di dati in vitro per convalidare e dimostrare i vantaggi unici della sua tecnologia a potenziali investitori e partner di licenza.<\/p>\n

Il team fondatore di Amporin comprende il CEO Dr. Kelvin Stott, il CSO Dr. Herv\u00e9 Schaffhauser e il CMO Prof. Daniel Umbricht, ognuno dei quali vanta oltre 20 anni di esperienza nello sviluppo di farmaci per il sistema nervoso centrale e nella conduzione di attivit\u00e0 di ricerca e sviluppo in diverse grandi aziende farmaceutiche e start-up biotecnologiche.<\/p>\n

\"Venture Kick \u00e8 stato fondamentale per aiutarci a costruire un'azienda di livello mondiale con una tecnologia che ha cambiato il mondo\", sottolinea Kelvin Stott, cofondatore e CEO di Amporin Pharmaceuticals. \"Senza Venture Kick, non avremmo avuto l'opportunit\u00e0 di realizzare il nostro potenziale\".<\/p>\n

Fonte: www.venturekick.ch<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"

Amporin Pharmaceuticals ha ricevuto un investimento di 150.000 franchi svizzeri da Venture Kick per promuovere lo sviluppo di inibitori dei pori amiloidi per il trattamento di malattie degenerative fatali.<\/p>","protected":false},"author":380,"featured_media":20150,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3303],"tags":[5551,3327,3352,5549],"class_list":["post-20148","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-qualitaetsmanagement","tag-investition","tag-qualitaetsmanagement","tag-unternehmen","tag-venture-kick"],"acf":[],"yoast_head":"\nAmporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t<\/title>\n<meta name=\"description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.m-q.ch\/it\/amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta property=\"og:description\" content=\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.m-q.ch\/it\/amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick\/\" \/>\n<meta property=\"og:site_name\" content=\"MQ Management und Qualit\u00e4t\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ManagementUndQualitaet\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-29T05:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"680\" \/>\n\t<meta property=\"og:image:height\" content=\"392\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Adelisa Kalajdzini\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick\" \/>\n<meta name=\"twitter:description\" content=\"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Adelisa Kalajdzini\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minuti\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"author\":{\"name\":\"Adelisa Kalajdzini\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\"},\"headline\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"keywords\":[\"Investition\",\"Qualit\u00e4tsmanagement\",\"Unternehmen\",\"Venture Kick\"],\"articleSection\":[\"Qualit\u00e4tsmanagement\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"url\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\",\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick - MQ Management und Qualit\u00e4t\",\"isPartOf\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"datePublished\":\"2024-07-29T05:48:13+00:00\",\"description\":\"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg\",\"width\":680,\"height\":392,\"caption\":\"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Qualit\u00e4tsmanagement\",\"item\":\"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#website\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"name\":\"MQ Management und Qualit\u00e4t\",\"description\":\"Plattform f\u00fcr integrierte Managementsysteme.\",\"publisher\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#organization\",\"name\":\"Galledia Fachmedien AG\",\"url\":\"https:\/\/www.m-q.ch\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"contentUrl\":\"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png\",\"width\":512,\"height\":512,\"caption\":\"Galledia Fachmedien AG\"},\"image\":{\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ManagementUndQualitaet\",\"https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175\",\"name\":\"Adelisa Kalajdzini\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g\",\"caption\":\"Adelisa Kalajdzini\"},\"url\":\"https:\/\/www.m-q.ch\/it\/author\/adelisa-kalajdzini\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick - MQ Gestione e Qualit\u00e0","description":"Amporin ha ricevuto un investimento di 150.000 franchi svizzeri da Venture Kick per promuovere lo sviluppo di inibitori dei pori amiloidi.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.m-q.ch\/it\/amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick\/","og_locale":"it_IT","og_type":"article","og_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","og_description":"Amporin hat von Venture Kick eine Investition von CHF 150'000 erhalten, um die Entwicklung von Amyloid-Poren-Inhibitoren voranzutreiben.","og_url":"https:\/\/www.m-q.ch\/it\/amporin-pharmaceuticals-riceve-150000-chf-da-venture-kick\/","og_site_name":"MQ Management und Qualit\u00e4t","article_publisher":"https:\/\/www.facebook.com\/ManagementUndQualitaet","article_published_time":"2024-07-29T05:48:13+00:00","og_image":[{"width":680,"height":392,"url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","type":"image\/jpeg"}],"author":"Adelisa Kalajdzini","twitter_card":"summary_large_image","twitter_title":"Amporin Pharmaceuticals erh\u00e4lt CHF 150'000 von Venture Kick","twitter_description":"#Amporin hat von #Venture #Kick eine #Investition von CHF 150'000 erhalten, um die #Entwicklung von #Amyloid-Poren-Inhibitoren voranzutreiben.","twitter_image":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","twitter_misc":{"Scritto da":"Adelisa Kalajdzini","Tempo di lettura stimato":"3 minuti"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#article","isPartOf":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"author":{"name":"Adelisa Kalajdzini","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175"},"headline":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick","datePublished":"2024-07-29T05:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"},"wordCount":375,"publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","keywords":["Investition","Qualit\u00e4tsmanagement","Unternehmen","Venture Kick"],"articleSection":["Qualit\u00e4tsmanagement"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","url":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/","name":"Amporin Pharmaceuticals riceve 150.000 franchi da Venture Kick - MQ Gestione e Qualit\u00e0","isPartOf":{"@id":"https:\/\/www.m-q.ch\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"image":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage"},"thumbnailUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","datePublished":"2024-07-29T05:48:13+00:00","description":"Amporin ha ricevuto un investimento di 150.000 franchi svizzeri da Venture Kick per promuovere lo sviluppo di inibitori dei pori amiloidi.","breadcrumb":{"@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/"]}]},{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#primaryimage","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2024\/07\/Amporin_Bild1_ps.jpg","width":680,"height":392,"caption":"Amporin Mitbegr\u00fcnder: CSO Dr. Herv\u00e9 Schaffhauser, CEO Dr. Kelvin Stott, und CMO Prof. Daniel Umbricht. (Bild: www.venturekick.ch)"},{"@type":"BreadcrumbList","@id":"https:\/\/www.m-q.ch\/amporin-pharmaceuticals-erhaelt-chf-150000-von-venture-kick\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Qualit\u00e4tsmanagement","item":"https:\/\/www.m-q.ch\/kategorie\/qualitaetsmanagement\/"},{"@type":"ListItem","position":2,"name":"Amporin Pharmaceuticals erh\u00e4lt CHF 150’000 von Venture Kick"}]},{"@type":"WebSite","@id":"https:\/\/www.m-q.ch\/fr\/#website","url":"https:\/\/www.m-q.ch\/fr\/","name":"Gestione e qualit\u00e0 MQ","description":"Piattaforma per sistemi di gestione integrati.","publisher":{"@id":"https:\/\/www.m-q.ch\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.m-q.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/www.m-q.ch\/fr\/#organization","name":"Galledia Fachmedien AG","url":"https:\/\/www.m-q.ch\/fr\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","contentUrl":"https:\/\/www.m-q.ch\/wp-content\/uploads\/2020\/12\/cropped-logo_small.png","width":512,"height":512,"caption":"Galledia Fachmedien AG"},"image":{"@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ManagementUndQualitaet","https:\/\/www.linkedin.com\/showcase\/17982321\/admin\/"]},{"@type":"Person","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/4ebe2e04afdd80427ae9c9069dde7175","name":"Adelisa Kalajdzini","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/www.m-q.ch\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2b95b0122f29123fee33229802f3b16b?s=96&d=mm&r=g","caption":"Adelisa Kalajdzini"},"url":"https:\/\/www.m-q.ch\/it\/author\/adelisa-kalajdzini\/"}]}},"_links":{"self":[{"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/posts\/20148","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/users\/380"}],"replies":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/comments?post=20148"}],"version-history":[{"count":2,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/posts\/20148\/revisions"}],"predecessor-version":[{"id":20151,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/posts\/20148\/revisions\/20151"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/media\/20150"}],"wp:attachment":[{"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/media?parent=20148"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/categories?post=20148"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.m-q.ch\/it\/wp-json\/wp\/v2\/tags?post=20148"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}